TC BioPharm (TCBP) said Monday it completed dosing for the first group B patient in the Achieve Phase 2B UK trial assessing TCB008 in acute myeloid leukemia.
The first group B patient received the dose in October, the company said, adding the person has received all four planned doses of TCB008 and is expected to get an additional fifth dose.
Meanwhile, enrollment of a second group B patient has also been started, the company said, adding group B recruitment is also continuing at sites in the UK.
"The therapy has been well-tolerated with no unexpected events or toxicities observed and promising efficacy results observed in some patients, with additional data being collected and analyzed," said TC BioPharm Chief Executive Bryan Kobel.
The company expects to complete enrollment in the second group in H1 2025, and data readout is expected later this year, Kobel said.
The company's shares were down past 6% in recent trading.
Price: 3.77, Change: -0.26, Percent Change: -6.45
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。